Clinical Trials Logo

Clinical Trial Summary

Rationale: Lung cancer is the predominant cancer type worldwide in terms of incidence and mortality. Novel treatment techniques are continuously being developed, all of which need thorough evaluation before they can be implemented in clinical routine. The gold standard design for such evaluation is the randomized controlled trial (RCT), but this design has shown many challenges, particularly in the oncology setting. The 'Trials within Cohorts' (TwiCs) design, previously referred to as 'cohort multiple RCT' (cmRCT), is a promising design enabling multiple (simultaneous) randomized evaluations of experimental interventions, with advantages for recruitment, comparability, and long-term outcome data collection. This design will speed up the process of translating treatment innovations in daily clinical practice. Objective: 1) To collect information on patient characteristics, short- and long-term clinical and patient-reported outcomes; and 2) to create an infrastructure for efficient, fast, and pragmatic randomized evaluation of new interventions. Study design: Observational, prospective cohort study, according to the 'TwiCs' design. Study population: All patients with lung cancer referred to the Department of Pulmonology or the Department of Radiotherapy of the UMC Utrecht. Main study parameters/endpoints: Clinical parameters (performance status, co-morbidity, oncological history, symptoms, imaging, technical and treatment data), clinical endpoints (toxicity, reintervention and survival), and patient-reported outcomes.


Clinical Trial Description

The basis of the TwiCs approach is an observational prospective cohort, consisting of patients with the same condition of interest, who undergo standard treatment. The patient characteristics are captured at baseline, and clinical and patient-reported outcome measures are captured at fixed time points. When a new intervention is ready for formal evaluation, eligible patients within the observational cohort are identified. From this so-called sub-cohort, patients will be randomly selected to undergo the new intervention. The other eligible patients will not be approached and undergo the standard treatment. Outcomes of the selected patients receiving the new intervention will be compared with the outcomes of the non-selected patients receiving the standard treatment. Within this cohort, the same process can be simultaneously repeated for other interventions. Advantages of the TwiCs design include ongoing information as to the natural history of the condition and to treatment as usual, the ability to facilitate multiple simultaneous randomized evaluations, the improved comparability between trials, and the patient-centered informed consent procedure. By setting up the prospective U-COLOR cohort (Utrecht COhort for Lung cancer Outcome Reporting and trial inclusion), we aim to: - Gather data on natural disease progression, treatment response, disease recurrence, complications, quality of life and survival of patients with lung cancer; - Collect a patient group willing to participate in studies; - Facilitate multiple, parallel randomized controlled trials within the cohort. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05069792
Study type Observational
Source UMC Utrecht
Contact Pim JJ Damen, MD
Phone +31(0)887553139
Email [email protected]
Status Recruiting
Phase
Start date July 1, 2020
Completion date July 2030

See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Completed NCT00245154 - Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer Phase 2/Phase 3
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Completed NCT01000025 - PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer Phase 3
Not yet recruiting NCT04563234 - Perioperative Cognitive Training in Thoracic Surgery N/A
Not yet recruiting NCT04934865 - Real Life Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients : REAL-MOOV-LUNG N/A
Recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Active, not recruiting NCT02196844 - Yoga Program for Lung Cancer Patients and Caregivers N/A
Recruiting NCT04957433 - 'Lung Health Check' Biomarker Study
Recruiting NCT04500535 - A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03317080 - Dynamic Monitoring Circulating Tumor DNA in Surgical Patients With Lung Cancer